Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Gene Ther. 2011 Dec 15;20(1):7–15. doi: 10.1038/gt.2011.205

Figure 4.

Figure 4

Activation of innate immunity by MV. PBMC were treated overnight with MV (MOI 1). A; Chromium release elicited from labelled Mel888 targets on 4 hour culture with MV-treated PBMC. B; Levels of CD69 on CD3-CD56+ NK cells with or without treatment with MV. C; CD107 upregulation on CD3-CD56+ NK cells within PBMC, following four hour co-culture with Mel888. All figures are representative of experiments in three healthy donors.